# P & F Sorscher

> **NIH NIH P30** · EMORY UNIVERSITY · 2021 · $85,703

## Abstract

Pilot and feasibility projects within the P30 Center will contribute to multidisciplinary research at Emory and
affiliated institutions, enhance faculty development, extensively utilize scientific cores, and integrate well with
the global research themes of our cystic fibrosis (CF) research program. A strong commitment to basic and
translational aspects of CF science (and NIDDK-relevant sequelae of the disease in particular), together with
substantial institutional support, momentum, and innovation, are described by this proposal. Infrastructure and
methodologies for solicitation, review, and advancement of pilot projects are in place, and have been
successfully utilized at Emory for many years. The P30 Pilot and Feasibility component will serve as a key
element within an intellectual environment for cystic fibrosis research that is well-established and growing
rapidly. Specific Aims of the Pilot and Feasibility component are as follows:
Specific Aim 1. Provide research support that will enable eligible investigators to explore the feasibility
of innovative, high-risk concepts directed towards CF basic biomedical, clinical, and translational
research. Projects typically last two years, are concordant with the overall objectives of the P30, and are
expected to result in further grant support from NIH or other funding agencies.
Specific Aim 2. Provide an administrative framework for oversight and review of Pilot and Feasibility
studies. This includes recommendations regarding continuation (or termination) of pilots to the P30 Program
Steering Committee, solicitation and review of pilot applications, record-keeping with regard to grant and
manuscript productivity of pilot investigators, tracking subsequent career events of awardees, and all aspects
of program management.
Two Pilot and Feasibility projects are recommended for NIH funding based on study section-type review
and prioritization as described in the submission. Research summaries are provided for Project 1 (“Role of
Programmed Cell Death (PCD) Signaling in Inflammatory Intestinal Injury”) and Project 2 (“Deep Phenotyping
of Cystic Fibrosis-Related Diabetes Integrating Small Molecule -Omics and Clinical Outcomes”). Support
through the NIH P30 mechanism will advance novel findings relevant to NIDDK-prioritized aspects of CF
pathogenesis and treatment. Pilot and Feasibility projects will engage a long-standing passion among our
faculty to develop novel and better therapies for cystic fibrosis, and furnish an engine to drive innovation.

## Key facts

- **NIH application ID:** 10260488
- **Project number:** 5P30DK125013-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Eric J SORSCHER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $85,703
- **Award type:** 5
- **Project period:** 2020-09-10 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260488

## Citation

> US National Institutes of Health, RePORTER application 10260488, P & F Sorscher (5P30DK125013-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10260488. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*